{
    "Trade/Device Name(s)": [
        "Optilite Rheumatoid Factor Kit"
    ],
    "Submitter Information": "The Binding Site Group Ltd.",
    "510(k) Number": "K162263",
    "Predicate Device Reference 510(k) Number(s)": [
        "K160070"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DHR"
    ],
    "Summary Letter Date": "April 6, 2017",
    "Summary Letter Received Date": "April 7, 2017",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.5775"
    ],
    "Regulation Name(s)": [
        "Rheumatoid factor immunological test system"
    ],
    "Analyte Class(es)": [
        "immunology"
    ],
    "Analyte(s)": [
        "Rheumatoid factor"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Binding Site Optilite analyser"
    ],
    "Method(s)/Technology(ies)": [
        "Immunoturbidimetry",
        "Turbidimetric analysis"
    ],
    "Methodologies": [
        "Quantitative immunoturbidimetric assay"
    ],
    "Submission Type(s)": [
        "Kit",
        "Calibrator",
        "Control",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Optilite Rheumatoid Factor Kit using quantitative immunoturbidimetry on the Optilite analyser for measurement of rheumatoid factor in serum",
    "Indications for Use Summary": "Intended for the quantitative in vitro measurement of rheumatoid factor in serum using the Binding Site Optilite analyser; measurement may aid in the diagnosis of rheumatoid arthritis and should be used in conjunction with other laboratory and clinical findings.",
    "fda_folder": "Immunology"
}